Afrezza: some questions about a new approach to prandial insulin.

Abstract

On June 27, the US Food and Drug Administration (FDA) announced its approval of Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus, citing this as a “new treatment option [which] broadens the options available for delivering mealtime insulin”. Although associated with less… (More)
DOI: 10.1111/1753-0407.12217

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics